Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

For further information, see CMDT Part 9-22: Sarcoidosis

Key Features

Essentials of Diagnosis

  • Symptoms related to sarcoid involvement of

    • Lung

    • Skin

    • Eyes

    • Peripheral nerves

    • Liver

    • Kidney

    • Heart

    • Other tissues

  • Demonstration of noncaseating granulomas in biopsy specimen

  • Exclusion of other granulomatous disorders

General Considerations

  • A systemic disease of unknown etiology

  • Granulomatous inflammation of the lungs is present in 90% of cases

  • Assessment of pulmonary hypertension is recommended in advanced disease

Demographics

  • Highest incidence in North American Blacks and northern European Whites

  • Among Blacks, women are more frequently affected than men

  • Disease onset is usually in the third or fourth decade

Clinical Findings

Symptoms and Signs

  • Malaise, fever, and insidious dyspnea

  • Erythema nodosum, iritis, peripheral neuropathy, arthritis

  • Parotid gland enlargement, hepatosplenomegaly, and lymphadenopathy

  • Some patients are asymptomatic, and diagnosis is made after abnormal findings are noted on chest radiograph

  • Crackles are uncommon on chest examination

  • Myocardial sarcoidosis found in 5% of patients can lead to

    • Restrictive cardiomyopathy

    • Cardiac dysrhythmias

    • Conduction disturbances

Differential Diagnosis

  • Other granulomatous diseases must be excluded

    • Tuberculosis

    • Histoplasmosis

    • Coccidioidomycosis

  • Lymphoma (including lymphocytic interstitial pneumonitis)

  • Idiopathic pulmonary fibrosis

  • Pneumoconiosis (especially berylliosis)

  • Syphilis

Diagnosis

Laboratory Tests

  • Leukopenia

  • Elevation of erythrocyte sedimentation rate

  • Hypercalcemia in 5%, hypercalciuria in 20%

  • Angiotensin-converting enzyme (ACE) levels

    • Commonly elevated in active disease

    • Neither sensitive nor specific enough to be of diagnostic value

  • Physiologic testing may reveal evidence of airflow obstruction, but restrictive changes with decreased lung volumes and diffusing capacity are more common

  • Skin test anergy is present in 70%

Imaging Studies

  • Radiographic findings are variable

    • Stage I: hilar adenopathy alone

    • Stage II: hilar adenopathy with parenchymal involvement

    • Stage III: parenchymal involvement alone

    • Stage IV: advanced fibrotic changes principally in the upper lobes

  • Parenchymal involvement usually manifests as diffuse reticular infiltrates, but focal infiltrates, acinar shadows, nodules, and rare cavitation are seen

  • Pleural effusion occurs in < 10% of patients

  • Cardiac magnetic resonance imaging (MRI) is favored over positron emission tomography (PET) scan for patients with suspected cardiac involvement

Diagnostic Procedures

  • ECG may show conduction disturbances and dysrhythmias

  • Biopsy demonstrating noncaseating granulomas is required for diagnosis

    • Easily accessible biopsy sites include lymph nodes, skin lesions, and salivary glands

    • Transbronchial biopsy has a yield of 75–90%

    • Some experts believe biopsy is unnecessary in stage I disease with a presentation highly suggestive of sarcoidosis

  • Bronchoalveolar lavage is usually characterized by an increase in lymphocytes with a high CD4/CD8 ratio; this may be used to follow disease activity, but not for diagnosis

Treatment

Medications

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.